EXAS
Price
$53.36
Change
-$0.50 (-0.93%)
Updated
Jul 3 closing price
Capitalization
12.78B
32 days until earnings call
RGEN
Price
$127.47
Change
+$0.51 (+0.40%)
Updated
Jul 3 closing price
Capitalization
10.26B
32 days until earnings call
Interact to see
Advertisement

EXAS vs RGEN

Header iconEXAS vs RGEN Comparison
Open Charts EXAS vs RGENBanner chart's image
Exact Sciences
Price$53.36
Change-$0.50 (-0.93%)
Volume$1.67M
Capitalization12.78B
Repligen
Price$127.47
Change+$0.51 (+0.40%)
Volume$208.77K
Capitalization10.26B
EXAS vs RGEN Comparison Chart in %
Loading...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXAS vs. RGEN commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXAS is a Hold and RGEN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (EXAS: $53.36 vs. RGEN: $127.47)
Brand notoriety: EXAS: Notable vs. RGEN: Not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EXAS: 53% vs. RGEN: 27%
Market capitalization -- EXAS: $12.78B vs. RGEN: $10.26B
EXAS [@Medical Specialties] is valued at $12.78B. RGEN’s [@Medical Specialties] market capitalization is $10.26B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXAS’s FA Score shows that 0 FA rating(s) are green whileRGEN’s FA Score has 1 green FA rating(s).

  • EXAS’s FA Score: 0 green, 5 red.
  • RGEN’s FA Score: 1 green, 4 red.
According to our system of comparison, both EXAS and RGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXAS’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 3 bullish TA indicator(s).

  • EXAS’s TA Score: 4 bullish, 5 bearish.
  • RGEN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, EXAS is a better buy in the short-term than RGEN.

Price Growth

EXAS (@Medical Specialties) experienced а +2.99% price change this week, while RGEN (@Medical Specialties) price change was +2.62% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.93%. For the same industry, the average monthly price growth was +1.81%, and the average quarterly price growth was -0.17%.

Reported Earning Dates

EXAS is expected to report earnings on Aug 05, 2025.

RGEN is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Medical Specialties (+1.93% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXAS($12.8B) has a higher market cap than RGEN($10.3B). EXAS YTD gains are higher at: -5.036 vs. RGEN (-11.442). RGEN has higher annual earnings (EBITDA): 134M vs. EXAS (29.3M). EXAS (778M) and RGEN (751M) have equal amount of cash in the bank . RGEN has less debt than EXAS: RGEN (712M) vs EXAS (2.56B). EXAS has higher revenues than RGEN: EXAS (2.5B) vs RGEN (639M).
EXASRGENEXAS / RGEN
Capitalization12.8B10.3B124%
EBITDA29.3M134M22%
Gain YTD-5.036-11.44244%
P/E RatioN/A247.52-
Revenue2.5B639M391%
Total Cash778M751M104%
Total Debt2.56B712M359%
FUNDAMENTALS RATINGS
EXAS vs RGEN: Fundamental Ratings
EXAS
RGEN
OUTLOOK RATING
1..100
5714
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
9690
PRICE GROWTH RATING
1..100
5256
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXAS's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for RGEN (95). This means that EXAS’s stock grew somewhat faster than RGEN’s over the last 12 months.

RGEN's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as EXAS (100). This means that RGEN’s stock grew similarly to EXAS’s over the last 12 months.

RGEN's SMR Rating (90) in the Biotechnology industry is in the same range as EXAS (96). This means that RGEN’s stock grew similarly to EXAS’s over the last 12 months.

EXAS's Price Growth Rating (52) in the Biotechnology industry is in the same range as RGEN (56). This means that EXAS’s stock grew similarly to RGEN’s over the last 12 months.

RGEN's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for EXAS (100). This means that RGEN’s stock grew significantly faster than EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXASRGEN
RSI
ODDS (%)
Bearish Trend 4 days ago
78%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
70%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 17 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BALFX36.850.18
+0.49%
American Funds American Balanced F1
IENAX30.58N/A
N/A
Invesco Energy A
JDSRX21.55N/A
N/A
Janus Henderson Small Cap Value R
WVCCX34.38N/A
N/A
abrdn International Small Cp A
FZALX28.63N/A
N/A
Fidelity Advisor Mega Cap Stock Z

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with QGEN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then QGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
-0.93%
QGEN - EXAS
55%
Loosely correlated
-0.62%
RGEN - EXAS
55%
Loosely correlated
+0.40%
ILMN - EXAS
36%
Loosely correlated
+0.46%
CDNA - EXAS
35%
Loosely correlated
-1.28%
A - EXAS
33%
Loosely correlated
+0.60%
More